Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
mediaposted on 2021-03-26, 08:32 authored by Kiyotaka Yoh, Tomonori Hirashima, Hideo Sakai, Takayasu Kurata, Yuichiro Ohe, Toyoaki Hida, Anders Mellemgaard, Remy B Verheijen, Xiaoling Ou, Ghada F. Ahmed, Manabu Hayama, Ko Sugibayashi, Geoffrey R. Oxnard
The above Plain Language Summary represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.